Herantis Pharma
@herantis.com
Herantis Pharma is a publicly listed drug development company aiming to revolutionize the treatment of diseases with unmet clinical needs.
Herantis Pharma's Company Logos
Herantis Pharma's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#35568C
Chambray
53, 86, 140
217, 45, 38
62, 39, 0, 45
#5798D0
Danube
87, 152, 208
208, 56, 58
58, 27, 0, 18
#7A1797
Seance
122, 23, 151
286, 74, 34
19, 85, 0, 41
About Herantis Pharma
Herantis Pharma is a publicly listed drug development company that aims to revolutionize the treatment of diseases with unmet clinical needs. They specialize in developing innovative therapies for better lives, with a particular focus on Parkinson's disease. Their lead product, HER-096, is an advanced small synthetic chemical peptidomimetic molecule, developed based on the active site of the parent CDNF protein.
What sets HER-096 apart is its compelling mechanism of action combined with the convenience of subcutaneous administration. Currently, Herantis is conducting a Phase 1a clinical study to assess the safety, tolerability, and blood-brain barrier penetration of subcutaneously administered HER-096. Top-line data from this study is expected by the end of 2023.
Herantis Pharma's shares are listed on the Nasdaq First North Growth Market Finland. With a mission to develop disease-modifying therapies, Herantis Pharma is dedicated to improving the lives of patients with Parkinson's disease and other unmet clinical needs
Company type
Public Company
Year founded
2008
Company size
11-50 employees
